# IMBdx

Source: https://onco.cc/companies/imbdx/  
OnCo record `imbdx` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A Seoul liquid biopsy company that offers CancerFind, a methylation blood test for several cancers, at Korean screening centres.

## Summary

IMBdx, based in Geumcheon-gu, Seoul, makes cell-free DNA tests including CancerFind, a whole-genome methylation and fragmentomics multi-cancer test published in Experimental and Molecular Medicine (2023, 2026).

## Fields

- Kind: Company
- Last checked: 2026-10-29
- HQ: Seoul
- Type: diagnostics
- Website: https://www.imbdx.com/

## Sources

- Official website: https://www.imbdx.com/

## Connected records

- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/), [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [Cell-free DNA methylation tests](https://onco.cc/technologies/cfdna-methylation-testing/), [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)
- drugs: [CancerFind](https://onco.cc/drugs/cancerfind/)

---
JSON: https://onco.cc/api/v1/entities/imbdx.json